Mechanisms of trastuzumab resistance and their clinical implications

Keng Hsueh Lan; Chien Hsing Lu; Dihua Yu

doi:10.1196/annals.1339.026

Mechanisms of trastuzumab resistance and their clinical implications

Keng Hsueh Lan, Chien Hsing Lu, Dihua Yu

Molecular & Cellular Oncology

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

Trastuzumab (Herceptin™) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.

Original language	English (US)
Pages (from-to)	70-75
Number of pages	6
Journal	Annals of the New York Academy of Sciences
Volume	1059
DOIs	https://doi.org/10.1196/annals.1339.026
State	Published - 2005

Keywords

Breast cancer
ErbB2
PI3K
PTEN
Resistance
Trastuzumab

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1196/annals.1339.026

Cite this

@article{b45b6dcd8a0648a5b01adf9d40938c4c,

title = "Mechanisms of trastuzumab resistance and their clinical implications",

abstract = "Trastuzumab (Herceptin{\texttrademark}) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.",

keywords = "Breast cancer, ErbB2, PI3K, PTEN, Resistance, Trastuzumab",

author = "Lan, {Keng Hsueh} and Lu, {Chien Hsing} and Dihua Yu",

year = "2005",

doi = "10.1196/annals.1339.026",

language = "English (US)",

volume = "1059",

pages = "70--75",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Mechanisms of trastuzumab resistance and their clinical implications

AU - Lan, Keng Hsueh

AU - Lu, Chien Hsing

AU - Yu, Dihua

PY - 2005

Y1 - 2005

N2 - Trastuzumab (Herceptin™) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.

AB - Trastuzumab (Herceptin™) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.

KW - Breast cancer

KW - ErbB2

KW - PI3K

KW - PTEN

KW - Resistance

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=32244435355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32244435355&partnerID=8YFLogxK

U2 - 10.1196/annals.1339.026

DO - 10.1196/annals.1339.026

M3 - Article

C2 - 16382045

AN - SCOPUS:32244435355

SN - 0077-8923

VL - 1059

SP - 70

EP - 75

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Mechanisms of trastuzumab resistance and their clinical implications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this